Close

Amicus Therapeutics (FOLD) Says it Was Granted FDA Orphan Drug Designation for ATB200/AT2221 for Pompe Disease

September 21, 2017 7:31 AM EDT Send to a Friend
Amicus Therapeutics (Nasdaq: FOLD) today announced the U.S. FDA has granted orphan drug designation to ATB200/AT2221 for the treatment of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login